Imaging Analysis Tool Enhancements Include Enterprise Access to Neuroradiology and Oncology Applications

A new release of a thin-client imaging analysis application brings significant enhancements to its earlier solutions in cardiac and other tools, and includes new optional neuroradiology and oncology applications.

Visage Imaging, Inc. (Carlsbad, CA,USA), a wholly owned subsidiary of Mercury Computer Systems, Inc., has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market its latest thin client product release, Visage CS 3.1. The Neuro option facilitates brain perfusion analysis in computed tomography (CT) and magnetic resonance imaging (MRI), while the oncology option provides tools for analyzing, documenting, and comparing lesions for multiple modalities, including standardized update value- (SUV)-based analysis for positron emission tomography-computed tomography (PET-CT) imaging.

"Visage Imaging's thin-client solution instantly brings workstation-class diagnostic tools to the numerous workplaces of those who need them,” said Hartmut Schirmacher, director of product management for Visage Imaging. "Compared to typical workstations or other web-based ‘fat' solutions, Visage CS offers far superior performance across the board, especially when viewing and processing large data volumes. Furthermore, Visage CS 3.1 will affordably allow for broader access to state-of-the-art applications throughout the enterprise.”

In addition to the new application options, Visage CS 3.1 features many new and streamlined measurement and post-processing tools such as advanced three-dimensional (3D) segmentation, region of interest- (ROI)-based analysis, and time-value curves, and improved editing of cardiac left ventricular (LV) models.

Related Links:
Visage Imaging